Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416631 | 0.91 | KMT2A (0.39) | SMPD3KMT2ASMN1; SMN2PDE10AHSD17B10 | |
| SCHEMBL2414785 | 0.89 | HRH4 (0.41) | KMT2ASMN1; SMN2PDE10AHSD17B10OGFRL1 | |
| SCHEMBL2410100 | 0.88 | KMT2A (0.42) | SMPD3KMT2ASMN1; SMN2PDE10AHSD17B10 | |
| SCHEMBL2413156 | 0.87 | KMT2A (0.45) | KMT2ASMN1; SMN2HSD17B10OGFRL1ALDH1A1 | |
| SCHEMBL2416683 | 0.85 | KMT2A (0.47) | KMT2ASMN1; SMN2HSD17B10OGFRL1ALDH1A1 | |
| SCHEMBL2415211 | 0.84 | GAA (0.43) | KMT2ASMN1; SMN2HSD17B10OGFRL1ALDH1A1 | |
| SCHEMBL2420524 | 0.83 | SMN1; SMN2 (0.39) | KMT2ASMN1; SMN2HSD17B10OGFRL1ALDH1A1 | |
| SCHEMBL2413257 | 0.83 | AKT1 (0.40) | SMPD3PDE10AOGFRL1 | |
| SCHEMBL2413440 | 0.81 | KMT2A (0.42) | KMT2ASMN1; SMN2HSD17B10OGFRL1ALDH1A1 | |
| SCHEMBL2415657 | 0.81 | PDE10A (0.50) | SMPD3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | claimed |
| US-6837908-B2 | 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2005-01-04 | — | — | US | claimed |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2003-09-04 | — | — | US | claimed |
| EP-1312606-A1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | L'OREAL (FR) | 2003-05-21 | — | — | EP | claimed |
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-6837908-B2 | 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| EP-1312606-A1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | L'OREAL (FR) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | KRT18, DPYD, DSP | SMPD3 3953/4885KMT2A 1344/4885SMN1; SMN2 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.